TY - JOUR
T1 - COVID-19 among patients with hematological malignancies
T2 - a national Israeli retrospective analysis with special emphasis on treatment and outcome
AU - Levy, Ilana
AU - Lavi, Avital
AU - Zimran, Eran
AU - Grisariu, Sigal
AU - Aumann, Shlomzion
AU - Itchaki, Gilad
AU - Berger, Tamar
AU - Raanani, Pia
AU - Harel, Reut
AU - Aviv, Ariel
AU - Lavi, Noa
AU - Zuckerman, Tsila
AU - Shvidel, Lev
AU - Jarchowsky, Osnat
AU - Ellis, Martin
AU - Herzog Tzarfati, Katrin
AU - Koren-Michowitz, Maya
AU - Sherf, Yehonatan
AU - Levi, Itai
AU - Sofer, Orit
AU - Shpilberg, Ofer
AU - Dally, Nagib
AU - Suriu, Celia
AU - Braester, Andrei
AU - Ben Barouch, Sharon
AU - Leiba, Merav
AU - Goldstein, Daniela
AU - Sarid, Nadav
AU - Yeganeh, Shay
AU - Halloun, Jabour
AU - Mittelman, Moshe
AU - Tadmor, Tamar
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.
AB - This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.
KW - COVID-19
KW - Haemato-oncological
KW - multicenter
KW - retrospective
UR - https://www.scopus.com/pages/publications/85113152555
U2 - 10.1080/10428194.2021.1966782
DO - 10.1080/10428194.2021.1966782
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34405767
AN - SCOPUS:85113152555
SN - 1042-8194
VL - 62
SP - 3384
EP - 3393
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -